Suppr超能文献

4014例2型糖尿病患者中1016例75岁以上患者使用HMG - CoA还原酶抑制剂预防脑血管意外的疗效

Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals.

作者信息

Hayashi Toshio, Kubota Kiyoshi, Kawashima Seinosuke, Sone Hirohito, Watanabe Hiroshi, Ohrui Takashi, Yokote Koutaro, Takemoto Minoru, Araki Atsushi, Noda Mitsuhiko, Noto Hiroshi, Sakuma Ichiro, Yoshizumi Masao, Ina Koichiro, Nomura Hideki

机构信息

Department of Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.

出版信息

Int J Cardiol. 2014 Dec 20;177(3):860-6. doi: 10.1016/j.ijcard.2014.10.093. Epub 2014 Nov 5.

Abstract

BACKGROUND/OBJECTIVES: HMG-CoA reductase inhibitors (statins) reduce ischemic heart disease (IHD) in middle-aged diabetic individuals, and LDL-cholesterol (LDL-C) is a risk factor. However, their preventive effects on cerebrovascular attack (CVA) have not been identified in elderly, especially in elderly ≥ 75 years (late elderly), who account for approximately 30% of diabetic individuals in Japan. Randomized controlled studies of statins for late elderly are difficult to carry out, because many co-morbidities in elderly disrupt randomized controlled conditions.

METHODS

We performed a prospective cohort study (Japan Cholesterol and Diabetes Mellitus Study) with 5.5 years of follow-up since 2004. A total of 4014 type 2 diabetic patients without previous IHD or CVA (n=1936 women; age = 67.4 ± 9.5 years; ≥ 75 years: n = 1016) were enrolled, while 405 patients were registered as sub-cohort patients. We recorded detailed information on medications and laboratory data after every change in medication in patients of sub-cohort and suffered from IHD or CVA. We subdivided statin-users into prevalent, new and non-users.

RESULTS

A total of 104 CVAs occurred during 5.5-years. Plasma HDL-C level was inversely correlated with CVA in patients ≥ 65 years. In case-control study, among patients who were not prescribed statins, CVA increased in age-dependent manner. CVA incidence was lower in prevalent and new statin-users than in non-users (hazard ratio [HR]:0.46, 0.523), especially in late elderly (HR: 0.51, 0.21). Statins reduced CVAs mainly due to a direct effect and partially due to the effects of HDL-C and glucose metabolism. No significant differences were observed between statins.

CONCLUSION

Statins prevented CVA in middle-aged, elderly and late elderly diabetic patients via a direct effect. This study is the first to demonstrate the usefulness of observational studies for statistically analyzing agents' effects on late elderly.

摘要

背景/目的:羟甲基戊二酸单酰辅酶A还原酶抑制剂(他汀类药物)可降低中年糖尿病患者的缺血性心脏病(IHD)风险,低密度脂蛋白胆固醇(LDL-C)是一个危险因素。然而,他汀类药物对脑血管意外(CVA)的预防作用在老年人中尚未明确,尤其是在75岁及以上的老年人(高龄老年人)中,这类人群在日本糖尿病患者中约占30%。由于老年人存在多种合并症,打乱了随机对照条件,因此很难对高龄老年人进行他汀类药物的随机对照研究。

方法

我们开展了一项前瞻性队列研究(日本胆固醇与糖尿病研究),自2004年起进行了5.5年的随访。共纳入4014例既往无IHD或CVA的2型糖尿病患者(其中女性1936例;年龄=67.4±9.5岁;75岁及以上者1016例),另有405例患者作为亚队列患者进行登记。我们记录了亚队列患者每次用药变更后以及发生IHD或CVA后的详细用药信息和实验室数据。我们将他汀类药物使用者细分为既往使用者、新使用者和非使用者。

结果

在5.5年期间共发生104例CVA。在65岁及以上患者中,血浆高密度脂蛋白胆固醇(HDL-C)水平与CVA呈负相关。在病例对照研究中,未服用他汀类药物的患者中,CVA的发生率随年龄增长而增加。既往使用者和新使用者的CVA发生率低于非使用者(风险比[HR]:0.46,0.523),在高龄老年人中尤其如此(HR:0.51,0.21)。他汀类药物降低CVA主要是由于直接作用,部分是由于HDL-C和糖代谢的作用。不同他汀类药物之间未观察到显著差异。

结论

他汀类药物通过直接作用预防了中年、老年和高龄老年糖尿病患者的CVA。本研究首次证明了观察性研究在统计学分析药物对高龄老年人的作用方面的有用性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验